Physician profile

Domys E Pena

Family · Orlando, FL

NPI 1013485739

$506.96

in general payments reported to CMS, 2019-2025

10 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$62.65
Education$42.08

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Astrazeneca Pharmaceuticals LP $177.05 2021
Novo Nordisk INC $65.81 2023 Rybelsus, Ozempic
Evoke Pharma, INC. $61.00 2021-2023 Gimoti
Bayer Healthcare Pharmaceuticals INC. $43.40 2021-2024
Abbvie INC. $43.09 2021
Amarin Pharma, INC. $34.97 2021
Janssen Pharmaceuticals, INC $31.89 2021
Phadia US INC. $18.19 2021
Lilly USA, LLC $17.36 2021
Novartis Pharmaceuticals Corporation $14.20 2022

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Domys E Pena

$506.96

in general payments reported 2019-2025

Years
2021-2024
Top company
Astrazeneca Pharmaceuticals LP

https://glasscript.com/doctor/10873261/domys-e-pena

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.